Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This study observes the safety and efficacy of Azacitidine (AZA) combined with ruxolitinib to
treat higher-risk Myelodysplastic Syndromes∕Myeloproliferative Neoplasms(MDS/MPN)
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Jiangbin Hospital Affiliated to Jiangsu University Jiangning Hospital Affiliated to Nanjing Medical University Nanjing Second Hospital